학술논문
P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study
Document Type
Abstract
Author
Source
In Oral Oncology July 2021 118 Supplement:7-8
Subject
Language
ISSN
1368-8375